Through the 90-day period concluding January 10, 2026, LENZ Therapeutics's top three insider stakeholders include TenPercentOwner Venture Capital Vi, L.P. Versant (1.81Mn shares), TenPercentOwner Biocapital, L.P. Samsara (1.21Mn shares), Director James W Mccollum (536.07K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Biocapital, L.P. Samsara | 1,208,498 | 13 Apr, 2022 | |
| Venture Capital Vi, L.P. Versant | 1,814,726 | 02 Oct, 2025 | |
| Davis Jerel | 243,965 | 01 Jul, 2021 | |
| Capital Management, L.P. Ra | 99,253 | 25 Mar, 2024 | |
| James W Mccollum | 536,065 | 10 Nov, 2025 | |
| Phil Gutry | Chief Business Officer | 42,850 | 13 Apr, 2022 |
| Marc Odrich | Chief Medical Officer | 14,229 | 25 Mar, 2024 |
| Evert B. Schimmelpennink | President And Ceo And Secretary | 49,200 | 07 Mar, 2025 |
| Daniel R. Chevallard | Chief Financial Officer | 5,386 | 07 Nov, 2025 |
| Shawn Olsson | Chief Commercial Officer | 4,733 | 19 Nov, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 17 Nov, 2025 | Shawn Olsson | Common Stock | D | 4,212 | $25.74 | 10,521 | D | S |
| 17 Nov, 2025 | Shawn Olsson | Common Stock | D | 5,788 | $26.37 | 4,733 | D | S |
| 17 Nov, 2025 | Shawn Olsson | Common Stock | A | 10,000 | $2.08 | 14,733 | D | M |
| 07 Nov, 2025 | James W Mccollum | Common Stock | A | 10,500 | $22.79 | 10,500 | D | P |
| 07 Nov, 2025 | Daniel R. Chevallard | Common Stock | A | 20 | $22.71 | 3,208 | D | P |
| 07 Nov, 2025 | Daniel R. Chevallard | Common Stock | A | 2,178 | $22.76 | 5,386 | D | P |
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | - | - | 764,250 | I | |||
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 83,066 | $46.41 | 1,050,776 | D | S |
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | - | - | 821,752 | I | |||
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | - | - | 1,050,599 | D | |||
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 123 | $47.01 | 764,127 | I | S |
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 57,502 | $46.41 | 764,250 | I | S |
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 34,405 | $45.35 | 821,752 | I | S |
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 49,701 | $45.35 | 1,133,842 | D | S |
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | - | - | 1,133,842 | D | |||
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 177 | $47.01 | 1,050,599 | D | S |
| 18 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 268 | $43.30 | 1,183,543 | D | S |
| 18 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 132 | $43.30 | 856,157 | I | S |
| 18 Sep, 2025 | Venture Capital Vi, L.P. Versant | - | - | 856,157 | I | |||
| 18 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 49,479 | $41.59 | 1,224,718 | D | S |